Fortress Biotech, Inc. Liquidation Value

Fortress Biotech (FBIO) presents deeply negative equity recovery under a liquidation lens as of March 31, 2026. The TAG_CONTEXT is empty — no XBRL tags were emitted in this filing submission as provided — so all quantitative observations below are sourced exclusively from narrative disclosures in the filing body and the prior filing body.

Key balance-sheet data from narrative: Total debt outstanding net of discount was $39.4 million at March 31, 2026 under the New Oaktree Agreement (2024 Oaktree Note, original draw $35.0 million, maturity extended to June 30, 2028 via First Amendment December 2025). The MFFAIS-computed latest cash liquidation value is approximately $2.2 million and operating liquidation value is approximately $41.6 million, both of which are dwarfed by face-value liabilities. Accumulated deficit stood at approximately $623.7 million at March 31, 2026, compared to $734.1 million at December 31, 2025 — this apparent reduction is likely attributable to the March 30, 2026 closing of the Cyprium Priority Review Voucher (PRV) asset sale for gross proceeds of $205 million, a portion of which flowed through the consolidated P&L. The filing confirms mandatory Oaktree prepayments from PRV proceeds reduced the outstanding Oaktree principal to $15.0 million by March 30, 2026, which post-dates the balance sheet date of March 31, 2026; the $39.4 million net debt figure therefore reflects the pre-prepayment position.

The asset base is predominantly intangibles (in-licensed pharmaceutical IP, product rights at Journey Medical subsidiary) which receive 0% recovery under the liquidation lens. Journey's dermatology product revenues (approximately $63.3 million for full-year 2025) represent the only tangible going-concern value, but the related intangible assets — including the Emrosi license (patents expiring January 2039, currently subject to Lupin Hatch-Waxman ANDA paragraph IV challenge) — carry no liquidation value. Inventory at Journey receives approximately 60 cents on the dollar; receivables at 90-95 cents.

The liability stack is compounded by: (1) $14.0 million in cumulated undeclared Series A Preferred dividends (9.375% perpetual preferred, dividend paused since July 5, 2024); (2) the Oaktree facility with a minimum liquidity covenant ($7.0 million, reduced to $2.0 million post-Cyprium PRV monetization event); (3) ASC 842 operating lease obligations on the New York office (subleased effective April 1, 2026, generating approximately $11.8 million base rent over the sublease term through August 2031, partially offsetting but not extinguishing the underlying lease obligation); and (4) contingent indemnification and guaranty exposures across subsidiaries.

The company has lost Form S-3 eligibility due to the preferred dividend pause, constraining future capital access to Form S-1 or exempt offerings — structurally more expensive and dilutive. Operating losses of approximately $7.7 million for Q1 2026 and $70.2 million for full-year 2025 confirm continued cash consumption. Management's 12-month going concern statement is present but conditioned on current cash levels. Filing does not separately XBRL-tag accumulated deficit, total debt, lease obligations, intangible assets, inventory, accounts receivable, or preferred dividend arrearage — all material balance sheet lines discussed in narrative are absent from TAG_CONTEXT.